These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 20648217)

  • 21. Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis.
    Ten Berg JM; de Veer A; Oldgren J; Steg PG; Zateyshchikov DA; Jansky P; Seung KB; Hohnloser SH; Lip GYH; Nordaby M; Kleine E; Bhatt DL; Cannon CP;
    JACC Cardiovasc Interv; 2019 Dec; 12(23):2331-2341. PubMed ID: 31806214
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen.
    Douketis JD; Johnson JA; Turpie AG
    Arch Intern Med; 2004 Jun; 164(12):1319-26. PubMed ID: 15226166
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Warfarin anticoagulation in hemodialysis patients: a systematic review of bleeding rates.
    Elliott MJ; Zimmerman D; Holden RM
    Am J Kidney Dis; 2007 Sep; 50(3):433-40. PubMed ID: 17720522
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of anticoagulation on endothermal ablation of the great saphenous vein.
    Sharifi M; Mehdipour M; Bay C; Emrani F; Sharifi J
    J Vasc Surg; 2011 Jan; 53(1):147-9. PubMed ID: 20864301
    [TBL] [Abstract][Full Text] [Related]  

  • 25. No increased bleeding events with continuation of oral anticoagulation therapy for patients undergoing cardiac device procedure.
    Li HK; Chen FC; Rea RF; Asirvatham SJ; Powell BD; Friedman PA; Shen WK; Brady PA; Bradley DJ; Lee HC; Hodge DO; Slusser JP; Hayes DL; Cha YM
    Pacing Clin Electrophysiol; 2011 Jul; 34(7):868-74. PubMed ID: 21410724
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anticoagulation therapy for patients with non-valvular atrial fibrillation: comparison of decision analytic model recommendations and real-world warfarin prescription use.
    Casciano JP; Singer DE; Kwong WJ; Fox ES; Martin BC
    Am J Cardiovasc Drugs; 2012 Oct; 12(5):313-23. PubMed ID: 22920047
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Postoperative hemorrhagic complications after elective laparoscopic cholecystectomy in patients receiving long-term anticoagulant therapy.
    Ercan M; Bostanci EB; Ozer I; Ulas M; Ozogul YB; Teke Z; Akoglu M
    Langenbecks Arch Surg; 2010 Mar; 395(3):247-53. PubMed ID: 19294412
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Parenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation.
    Akl EA; Gunukula S; Barba M; Yosuico VE; van Doormaal FF; Kuipers S; Middeldorp S; Dickinson HO; Bryant A; Schünemann H
    Cochrane Database Syst Rev; 2011 Jan; (1):CD006652. PubMed ID: 21249680
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Parenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation.
    Akl EA; Gunukula S; Barba M; Yosuico VE; van Doormaal FF; Kuipers S; Middeldorp S; Dickinson HO; Bryant A; Schünemann H
    Cochrane Database Syst Rev; 2011 Apr; (4):CD006652. PubMed ID: 21491396
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Results of an open-label, prospective study of anticoagulant therapy for atrial fibrillation in an outpatient anticoagulation clinic.
    Abdelhafiz AH; Wheeldon NM
    Clin Ther; 2004 Sep; 26(9):1470-8. PubMed ID: 15531009
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A meta-analysis of complications attributed to anticoagulation among patients following cutaneous surgery.
    Lewis KG; Dufresne RG
    Dermatol Surg; 2008 Feb; 34(2):160-4; discussion 164-5. PubMed ID: 18093204
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety of percutaneous left atrial appendage closure with the Amplatzer cardiac plug in patients with atrial fibrillation and contraindications to anticoagulation.
    Wiebe J; Bertog S; Franke J; Wettstein O; Lehn K; Hofmann I; Vaskelyte L; Sievert H
    Catheter Cardiovasc Interv; 2014 Apr; 83(5):796-802. PubMed ID: 24327462
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Estimated glomerular filtration rate is associated with major bleeding complications but not thromboembolic events, in anticoagulated patients taking warfarin.
    Wieloch M; Jönsson KM; Själander A; Lip GY; Eriksson N; Svensson PJ
    Thromb Res; 2013 Jun; 131(6):481-6. PubMed ID: 23351664
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation.
    Calkins H; Willems S; Gerstenfeld EP; Verma A; Schilling R; Hohnloser SH; Okumura K; Serota H; Nordaby M; Guiver K; Biss B; Brouwer MA; Grimaldi M;
    N Engl J Med; 2017 Apr; 376(17):1627-1636. PubMed ID: 28317415
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics.
    Fihn SD; Callahan CM; Martin DC; McDonell MB; Henikoff JG; White RH
    Ann Intern Med; 1996 Jun; 124(11):970-9. PubMed ID: 8624064
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study.
    Arihiro S; Todo K; Koga M; Furui E; Kinoshita N; Kimura K; Yamagami H; Terasaki T; Yoshimura S; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Nagakane Y; Kameda T; Hasegawa Y; Shibuya S; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Matsuki T; Homma K; Takasugi J; Tokunaga K; Sato S; Kario K; Kitazono T; Toyoda K;
    Int J Stroke; 2016 Jul; 11(5):565-74. PubMed ID: 26927811
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of intravenous phytonadione (vitamin K1) in patients on long-term oral anticoagulant therapy.
    Shields RC; McBane RD; Kuiper JD; Li H; Heit JA
    Mayo Clin Proc; 2001 Mar; 76(3):260-6. PubMed ID: 11243272
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation and management of atrial fibrillation.
    Ali S; Hong M; Antezano ES; Mangat I
    Cardiovasc Hematol Disord Drug Targets; 2006 Dec; 6(4):233-44. PubMed ID: 17378769
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Twelve-month outcome of patients with an established indication for oral anticoagulation undergoing coronary artery stenting and stratified by the baseline risk of bleeding: Insights from the Warfarin and Coronary Stenting (War-Stent) Registry.
    Rubboli A; Saia F; Sciahbasi A; Leone AM; Palmieri C; Bacchi-Reggiani ML; Calabrò P; Bordoni B; Piccalò G; Franco N; Nicolino A; Magnavacchi P; Vignali L; Mameli S; Dallago M; Maggiolini S; Steffanon L; Piovaccari G; Di Pasquale G;
    Cardiovasc Revasc Med; 2017 Sep; 18(6):425-430. PubMed ID: 28363682
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dalteparin as periprocedure anticoagulation for patients on warfarin and at high risk of thrombosis.
    Tinmouth AH; Morrow BH; Cruickshank MK; Moore PM; Kovacs MJ
    Ann Pharmacother; 2001 Jun; 35(6):669-74. PubMed ID: 11408982
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.